CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing tool derived from bacterial immune systems. Compared to earlier gene editing technologies (ZFNs, TALENs), CRISPR-Cas9 is simpler, cheaper (per-experiment cost dropped from thousands to tens of dollars), more efficient, and targetable to any genomic location by designing different guide RNAs.
## Mechanism
The CRISPR-Cas9 system has two core components: **Cas9 protein** (“molecular scissors” — a nuclease) and **guide RNA (gRNA)** (“navigation system” — an RNA molecule complementary to the target DNA sequence). The gRNA guides Cas9 to the target DNA sequence; Cas9 cuts the double-stranded DNA at the target site; the cell’s DNA repair machinery (NHEJ or HDR) activates, achieving gene knockout (NHEJ introduces errors, disrupting gene function) or precise replacement (HDR integrates an exogenous DNA template).
## Clinical Progress
**Blood disease cures**: CRISPR therapy Casgevy (Vertex + CRISPR Therapeutics) received FDA approval in December 2023, becoming the world’s first approved CRISPR gene editing therapy for sickle cell disease (SCD) and transfusion-dependent β-thalassemia. Clinical trial data show patients achieving long-term symptom-free remission, considered “functional cure.”
**Cancer immunotherapy**: CRISPR-edited T cells (knocking out immune checkpoint genes like PD-1 to enhance anti-tumor activity) as upgraded CAR-T, with multiple clinical trials underway.
**In vivo gene editing**: directly delivering CRISPR to specific tissues (liver) in patients without extracting cells for ex vivo editing. Intellia Therapeutics’ transthyretin amyloidosis (ATTR) treatment demonstrated significant efficacy in Phase II trials.
## Limitations and Next-Generation Tools
**Off-target effects**: Cas9 may cut DNA at non-target sites, creating potential safety risks. Improved tools: high-fidelity Cas9 variants (eSpCas9, HiFi Cas9) significantly reduce off-target rates.
**Base editing**: developed by David Liu’s team (Harvard/Broad Institute) — precisely substitutes single bases (C→T or A→G) without double-strand breaks, with higher safety profile, widely applied in genetic disease treatment.
**Prime editing**: a more precise tool from the same team, analogous to a “word processor’s find-and-replace” — any base substitution or small insertion/deletion with fewer side effects.
See [Synthetic Biology Overview](https://sunqi.org/synthetic-biology-overview-en/) and [Broad Institute CRISPR resources](https://www.broadinstitute.org/crispr).
